News

Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland

2 September 2022 – Swissmedic has temporarily authorised “Spikevax Bivalent Original/Omicron (mRNA-1273.214)” which is the first COVID-19 vaccine containing messenger ribonucleic acid (mRNA) against two coronavirus variants. Trials have shown that a booster dose with this bivalent vaccine produces a stronger immune response than a booster with Spikevax®, the original COVID-19 vaccine from Moderna against the Omicron variants BA.1 und BA.4/5. The side effects profile was similar to the second dose or the booster of the original vaccine, hence no new safety signals were found.

For more information, see here.

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

News

Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland

We use cookies